Scheen A.J., Charbonnel B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal. Diabetes Metab 2014, 40:176-185.
Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
Scheen A.J., Paquot N. Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013, 39:179-190.
Scheen A.J., Paquot N. Metabolic effects SGLT-2 inhibitors beyond increased glucosuria: a review of clinical evidence. Diabetes Metab 2014, 40:S4-S11.
Scheen AJ. Pharmacodynamics, efficacy and safety of SGLT-2 inhibitors for the treatment of type 2 diabetes. Drugs 2014 (in press).
Schernthaner G., Gross J.L., Rosenstock J., Guarisco M., Fu M., Yee J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013, 36:2508-2515.
Strojek K., Yoon K.H., Hruba V., Sugg J., Langkilde A.M., Parikh S. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther 2014, 5:267-283.
Lavalle-Gonzalez F.J., Januszewicz A., Davidson J., Tong C., Qiu R., Canovatchel W., et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013, 56:2582-2592.
Patel S., DeFronzo R., Lewin A., Liu D., Kaste R., Woerle H.J., et al. Fixed dose combinations of empagliflozin/linagliptin for 52 weeks as add-on to metformin in subjects with type 2 diabetes. Diabetologia 2014, 57(Suppl 1):S7. Abstract 1.
Hansen L., Zee P., Li W., Cook B., Hishberg B., Iqbal N., et al. Randomised, double-blind trial of dual add-on saxagliptin plus dapagliflozin vs saxagliptin or dapagliflozin add-one alone in poorly controlled type 2 diabetes on metformin. Diabetologia 2014, 57(Suppl 1):S8. abstract 4.
Scheen A.J., Van Gaal L.F. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2014, 2:911-922.
Tahrani A.A., Barnett A.H., Bailey C.J. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013, 1:140-151.
Gilbert R. SGLT-2 inhibition in patients with kidney disease. Diabetes Metab 2014, 40:S17-S22.
Vallon V., Thomson S.C. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol 2012, 74:351-375.
Thomas M., Jandeleit-Dahm K., Bonnet F. Beyond glycosuria: exploring the intra-renal effects of SGLT-2 inhibition in diabetes. Diabetes Metab 2014, 40:S12-S16.
Terami N., Ogawa D., Tachibana H., Hatanaka T., Wada J., Nakatsuka A., et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One 2014, 9:e100777.
Einarson T.R., Garg M., Kaur V., Hemels M.E. Composite endpoints in trials of type-2 diabetes. Diabetes Obes Metab 2014, 16:492-499.
